{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:30:26Z","timestamp":1793723426393,"version":"4.6.1"},"reference-count":49,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"2","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) and membranous nephropathy (MN) are associated with progression to chronic kidney disease and end-stage renal disease (ESRD), but evidence describing the full disease burden across countries remains limited and fragmented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objectives\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This targeted literature review (TLR) aimed to characterize the disease burden of LN and MN, including epidemiology and clinical, humanistic, and economic outcomes, and identify unmet needs and current knowledge gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted, nonsystematic search of MEDLINE and EMBASE was conducted for English-language articles published between January 2013 and August 2023 in the United States (US), the United Kingdom, Germany, France, China, and Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Searches identified 26 relevant articles for LN and 11 for MN. LN epidemiology studies were limited to the US; incidence was estimated at 1:100\u2009000, with higher risk in older individuals, females, and African Americans. MN is rare, with reported annual incidences of 10 to 12 per million in North America and 2 to 17 per million in Europe. Prevalence appears to be increasing for both diseases. LN was associated with substantial progression to ESRD, with 21.1% to 36.8% of patients progressing within 5 to 10 years. ESRD represented a major economic driver, with US monthly costs of approximately $15\u2009000 per patient with LN. MN burden data were more limited but indicated risk of severe long-term renal complications and ESRD. Humanistic burden data were sparse; reported health-related quality-of-life impacts include renal symptom domains not captured by generic instruments, indicating a need for disease-specific measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite evidence of substantial burden, important gaps remain. Epidemiological data were geographically limited, with incidence varying widely, potentially reflecting differences in populations, treatment eras, and ethnicity. Long-term data beyond 5 to 10 years were limited, and robust syntheses evaluating prognostic factors influencing progression to ESRD were lacking. The absence of renal-specific patient-reported outcome measures and inconsistent clinical definitions further limits comparability and treatment value assessment. LN and MN are associated with significant clinical, economic, and humanistic burden, especially for patients with ESRD, but certainty and generalizability are limited by the focused TLR methods and heterogeneous evidence base. More robust data would help characterize long-term outcomes and support more informed value assessments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.166255","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:31:07Z","timestamp":1791379867000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Evidence Gaps in the Epidemiology and Burden of Lupus Nephritis and Membranous Nephropathy: A Targeted Literature Review"],"prefix":"10.36469","volume":"13","author":[{"given":"Francesca","family":"Barion","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04spfxf63","id-type":"ROR","asserted-by":"publisher"}],"name":"argenx, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9200-6935","authenticated-orcid":true,"given":"Vasileios","family":"Pardalidis","sequence":"additional","affiliation":[{"name":"Avalere Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Robert","sequence":"additional","affiliation":[{"name":"Avalere Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kielar","sequence":"additional","affiliation":[{"name":"Avalere Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"10289","key":"ref1","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/s0140-6736(21)00578-x","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"B. H. Rovin","year":"2021","journal-title":"Lancet"},{"issue":"4S","key":"ref2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"ref3","article-title":"HAS. BENLYSTA (b\u00e9limumab) (glom\u00e9rulon\u00e9phrite lupique)"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18553\/jmcp.2022.21496","article-title":"Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States","volume":"29","author":"M. Dall'Era","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"ref5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/art.40818","article-title":"Comparative fracture risks among United States Medicaid enrollees with and without systemic lupus erythematosus","volume":"71","author":"S.K. Tedeschi","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"C. H. Feldman","year":"2013","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network","volume":"75","author":"M. Hocaoglu","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/09612033221146093","article-title":"The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States","volume":"32","author":"C. F. Bell","year":"2022","journal-title":"Lupus"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"e0276053","DOI":"10.1371\/journal.pone.0276053","article-title":"A low rate of end-stage kidney disease in membranous nephropathy: a single centre study over 2 decades","volume":"17","author":"J. Storrar","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/0886022x.2020.1792315","article-title":"Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study","volume":"42","author":"P. Yin","year":"2020","journal-title":"Ren Fail"},{"key":"ref11","article-title":"Glomerulonephritis","author":"A. M. Kazi","year":"2025"},{"issue":"45","key":"ref12","doi-asserted-by":"publisher","first-page":"e17658","DOI":"10.1097\/md.0000000000017658","article-title":"A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor","volume":"98","author":"Q. Zhang","year":"2019","journal-title":"Medicine"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/0886022x.2022.2068442","article-title":"Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels","volume":"44","author":"Y. Sun","year":"2022","journal-title":"Ren Fail"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.kint.2015.11.022","article-title":"Long-term graft outcomes and patient survival are lower posttransplant in patients with a primary renal diagnosis of glomerulonephritis","volume":"89","author":"R. Pruthi","year":"2016","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"786334","DOI":"10.3389\/fphar.2021.786334","article-title":"Efficacy and safety of different immunosuppressive therapies in patients with membranous nephropathy and high PLA2R antibody titer","volume":"12","author":"L. Deng","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"ref16","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2215\/CJN.05900420","article-title":"Infection-related acute care events among patients with glomerular disease","volume":"15","author":"D. A. Glenn","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","first-page":"10994","DOI":"10.1038\/s41598-020-67910-w","article-title":"Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases","volume":"10","author":"R. Hu","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"P. Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/acr.25025","article-title":"Performance of modified ALMS and BLISS criteria with standard of care treatment in two US health care systems","volume":"75","author":"A. Khosroshahi","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41371-021-00492-w","article-title":"Prognostic significance of hypertension at the onset of lupus nephritis in Chinese patients: prevalence and clinical outcomes","volume":"36","author":"R. Rong","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.mayocp.2017.10.021","article-title":"End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population","volume":"93","author":"J. J. Sim","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref22","article-title":"Lupus Nephritis","author":"R. Musa","year":"2025"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/ndt\/gfac286","article-title":"Total cortical interstitial inflammation predicts chronic kidney disease progression in patients with lupus nephritis","volume":"38","author":"M. D. Duong","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/rheumatology\/keaa491","article-title":"Assessing outcomes in a lupus nephritis cohort over a 40-year period","volume":"60","author":"E. Gisca","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"ref25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/art.40392","article-title":"Sex differences in health care utilization, end-stage renal disease, and mortality among Medicaid beneficiaries with incident lupus nephritis","volume":"70","author":"C. H. Feldman","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"ref26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/cjn.02350314","article-title":"ESRD from lupus nephritis in the United States, 1995\u20132010","volume":"10","author":"D. J. Sexton","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref27","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/rheumatology\/keaa103","article-title":"Outcomes of membranous and proliferative lupus nephritis\u2013analysis of a single-centre cohort with more than 30 years of follow-up","volume":"59","author":"F. Farinha","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"ref28","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10067-018-4115-1","article-title":"Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis","volume":"37","author":"E. Ntatsaki","year":"2018","journal-title":"Clin Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"882692","DOI":"10.3389\/fmed.2022.882692","article-title":"Long-term kidney prognosis and pathological characteristics of late-onset lupus nephritis","volume":"9","author":"N. Tian","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12882-019-1676-4","article-title":"Long-term predictive value of acute kidney injury classification in diffuse proliferative lupus nephritis with acute kidney injury","volume":"21","author":"T. Chen","year":"2020","journal-title":"BMC Nephrol"},{"issue":"10","key":"ref31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/acr.22562","article-title":"Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis","volume":"67","author":"J. A. Gomez-Puerta","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"ref32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3111\/13696998.2013.772058","article-title":"Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population","volume":"16","author":"D. E. Furst","year":"2013","journal-title":"J Med Econ"},{"issue":"2","key":"ref33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.25259\/ijn_317_23","article-title":"An updated review of membranous nephropathy","volume":"34","author":"O. Efe","year":"2024","journal-title":"Indian J Nephrol"},{"issue":"4","key":"ref34","doi-asserted-by":"publisher","first-page":"e37839","DOI":"10.7759\/cureus.37839","article-title":"Healthcare resource utilization and associated costs in patients with systemic lupus erythematosus diagnosed with lupus nephritis","volume":"15","author":"C. F. Bell","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"ref35","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"C. H. Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"ref36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.18553\/jmcp.2019.18456","article-title":"Patients with idiopathic membranous nephropathy: a real-world clinical and economic analysis of U.S. claims data","volume":"25","author":"T. A. Nazareth","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/ppa.s111725","article-title":"Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives","volume":"10","author":"N. Mozaffarian","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0961203317717082","article-title":"Disease-specific quality of life in patients with lupus nephritis","volume":"27","author":"M. Jolly","year":"2018","journal-title":"Lupus"},{"issue":"9","key":"ref39","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1002\/iid3.689","article-title":"Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study","volume":"10","author":"Y. Hu","year":"2022","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"ref40","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.kint.2018.12.018","article-title":"Health-related quality of life in glomerular disease","volume":"95","author":"P. A. Canetta","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"ref41","doi-asserted-by":"publisher","first-page":"e37763","DOI":"10.1371\/journal.pone.0037763","article-title":"Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function","volume":"7","author":"A. B. Lib\u00f3rio","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"ref42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000438844","article-title":"Lupus nephritis: a different disease in European patients?","volume":"1","author":"V. Tesar","year":"2015","journal-title":"Kidney Dis (Basel)"},{"issue":"8","key":"ref43","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.ekir.2023.05.019","article-title":"PLA2R antibody does not outperform conventional clinical markers in predicting outcomes in membranous nephropathy","volume":"8","author":"O. Ragy","year":"2023","journal-title":"Kidney Int Rep"},{"key":"ref44","article-title":"Membranous Nephropathy","author":"A. Alok","year":"2025"},{"issue":"1S","key":"ref45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/annrheumdis-2020-eular.3870","article-title":"OP0163 2019 Update of the joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"A. Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"ref47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"M. C. Hochberg","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"ref48","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"L. R. Sammaritano","year":"2025","journal-title":"Arthritis Care Res"},{"issue":"1","key":"ref49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"A. Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/166255-understanding-the-evidence-gaps-in-the-epidemiology-and-burden-of-lupus-nephritis-and-membranous-nephropathy-a-targeted-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:07:57Z","timestamp":1793722077000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/166255-understanding-the-evidence-gaps-in-the-epidemiology-and-burden-of-lupus-nephritis-and-membranous-nephropathy-a-targeted-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.166255","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}